Welcome to our dedicated page for Cbdmd SEC filings (Ticker: YCBD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The cbdMD, Inc. (NYSE American: YCBD) SEC filings page on Stock Titan brings together the company’s official regulatory disclosures from EDGAR with AI-supported summaries to help interpret key documents. cbdMD is a North Carolina corporation focused on hemp-derived cannabinoid products and related wellness brands, and its filings provide detailed insight into its operations, capital structure, and risk profile.
Investors can review annual reports on Form 10-K for discussions of cbdMD’s multi-brand business model spanning cbdMD, Paw CBD, ATRx Labs, and Herbal Oasis, along with risk factors, going concern language, and descriptions of its hemp-derived CBD and Delta-9 product lines. Quarterly reports on Form 10-Q offer interim financial statements and management discussion of sales trends, gross margins, and operating results.
cbdMD also files numerous current reports on Form 8-K that document material events. Recent 8-Ks describe preferred stock financings, the adoption of an equity compensation plan, regaining compliance with NYSE American listing standards, and the asset purchase of Gaia Botanicals, LLC, including the Bluebird Botanicals brand and online CBD marketplace. These filings outline terms of capital raises, equity designations, and key transaction details. Additional registration statements on Form S-1 and S-1/A cover resale registrations for shares issuable upon conversion of preferred stock and shares tied to an equity line of credit with an institutional investor.
On this page, AI-generated overviews can help explain complex sections of cbdMD’s 10-K and 10-Q filings, highlight significant items in 8-Ks, and summarize registration statements related to equity offerings. Users can also access information about equity compensation plans and preferred stock designations, and track any insider or significant shareholder activity reported in relevant forms. Combined, these SEC filings give a structured view of YCBD’s financial condition, financing arrangements, corporate governance, and strategic transactions, supporting deeper analysis of the company’s stock.
cbdMD, Inc. filed an S-1 registering the potential resale of up to 1,700,000 shares of common stock by selling shareholders. The registered shares are issuable upon conversion of Series B Convertible Preferred Stock sold on September 29, 2025 pursuant to Purchase Agreements. cbdMD will not receive proceeds from any resale of these shares.
The Series B Preferred is convertible at $1.00 per share, subject to anti‑dilution adjustments and a floor conversion price of $0.50 per share, and accrues dividends at 10% per annum, payable in cash or stock subject to equity conditions. A 4.99% beneficial ownership limitation applies to conversions. An exchange cap limits issuances without prior shareholder approval to 19.99% of pre‑transaction outstanding shares, identified as 1,782,518 shares.
Shares outstanding were 8,919,410 as of November 6, 2025. The company states 10,619,410 shares outstanding assuming full conversion at a $1.00 conversion price. cbdMD previously received $1,700,000 gross proceeds from the private placement of the Series B Preferred for working capital and general corporate purposes.
cbdMD, Inc. issued 1,700,000 shares of newly designated Series B Convertible Preferred Stock to four institutional investors for aggregate gross proceeds of $1,700,000 and net proceeds of $1,500,000, to be used for working capital. Each preferred share converts into common stock at a conversion price of $1.00 subject to anti-dilution and special conversion rights. The Series B accrues dividends at 10% per annum payable quarterly in common shares or cash subject to defined equity conditions; unpaid dividends may increase the stated value if cash payment is restricted by North Carolina law. The preferred ranks senior on liquidation, carries no voting rights except as required by law, and includes a 4.99% beneficial ownership cap on conversion. The company agreed to file a registration statement for the underlying common shares within 30 days of closing per registration rights agreements.